Haematological malignancies (blood cancers)

SNIPR Biome has dosed the first patient in its Phase 1b trial of SNIPR001, a CRISPR-CAS-armed bacteriophage therapy that represents a new frontier in...

Haematological malignancies (blood cancers)

Relapsed or Refractory Acute Myeloid Leukemia, AML, (NCT06541444)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.

IND Enabling

Phase I

Phase II

Phase III

Pediatric Relapsed or Refractory Acute Myeloid Leukemia, AML, (NCT06541405)
Sponsors:
Base Therapeutics (Shanghai) Co., Ltd.

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Acute Myeloid Leukaemia, AML, (NCT07026942)
Sponsors:
Nationwide Children's Hospital

IND Enabling

Phase I

Phase II

Phase III

Relapsed or refractory B-cell non-Hodgkin's lymphoma, (NCT06838832)
Sponsors:
Chinese PLA General Hospital

IND Enabling

Phase I

Phase II

Phase III

T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma, (NCT06514794)
Sponsors:
Wugen, Inc.

IND Enabling

Phase I

Phase II

Phase III

Relapsed or refractory B-cell hematological malignancies, (NCT05381181)
Sponsors:
Bioray Laboratories

IND Enabling

Phase I

Phase II

Phase III

Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma, (NCT06934382)
Sponsors:
Stephan Grupp MD PhD, Children's Hospital of Philadelphia

IND Enabling

Phase I

Phase II

Phase III

B-cell Non-Hodgkin Lymphoma, NHL, (NCT06321289)
Sponsors:
Chinese PLA General Hospital

IND Enabling

Phase I

Phase II

Phase III